Fourth-quarter and full-year earnings at Bristol-Myers Squibb beat estimates, but a report of the successful trial of the company's lung cancer treatment may be the big mover for the stock Monday.
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
Medical aesthetics company Evolus expects to price 5.0 million shares in a range that results in an initial public offering valued up to more than $80 million.
Merck reported mixed fourth-quarter financial results before the markets opened on Friday.
Cascadian Therapeutics saw its shares absolutely skyrocket on Wednesday after it was announced that Seattle Genetics would be acquiring the company. This is far and away the top-performing stock in Wednesday’s session.
Eli Lilly reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.
Three of America's best-known companies are creating an independent company with the goal to reducing costs and improving healthcare services for their employees. Health insurers are taking a hit to their stock prices.
Pharmaceuticals giant Pfizer beat quarterly and full-year expectations this morning, but the beats were small and the forecast for next year is not exhilarating.
While Zynerba's share price is still roughly half of last year's peak, the company has gotten attention from Wall Street with big upside in analyst calls in recent days.
This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and that can drive the interest in biotechs ever higher.
Johnson &; Johnson, Gilead Sciences and Amicus Therapeutics are among companies expecting clinical trial and FDA updates in February.
AbbVie reported better-than-expected fourth-quarter financial results before the markets opened on Friday.
24/7 Wall St. has noticed that analysts and investors seem to not be able to get enough of Abbott Laboratories.
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The January 12 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
